July 17, 2024

Supplementary Figure 5 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

This figure shows the selection of cell lines used for in vitro evaluation of the effects of amivantamab on the protein and surface levels EGFR, MET, LDHA and SLC16A3.

Supplementary Figure 5 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

Key Points

Abstract

Cite This Study